Cargando…

Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study

BACKGROUND: Patients with bronchiectasis are often treated with bronchodilators such as long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists (LABA) for their symptoms, but empirical evidence supporting such practice is sparse. We evaluated the effect of LAMA and LABA on lung functi...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Su Yeon, Lee, Jae Seung, Lee, Sei Won, Oh, Yeon-Mok
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867804/
https://www.ncbi.nlm.nih.gov/pubmed/33569197
http://dx.doi.org/10.21037/jtd-20-1282
_version_ 1783648346551877632
author Lee, Su Yeon
Lee, Jae Seung
Lee, Sei Won
Oh, Yeon-Mok
author_facet Lee, Su Yeon
Lee, Jae Seung
Lee, Sei Won
Oh, Yeon-Mok
author_sort Lee, Su Yeon
collection PubMed
description BACKGROUND: Patients with bronchiectasis are often treated with bronchodilators such as long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists (LABA) for their symptoms, but empirical evidence supporting such practice is sparse. We evaluated the effect of LAMA and LABA on lung function improvement in patients with bronchiectasis. METHODS: Using the in-house patient database at a tertiary referral hospital in Seoul, South Korea, we extracted data from patients diagnosed as bronchiectasis with computed tomography (CT) scan and treated with LAMA, LABA, or both. Patients with asthma, chronic obstructive pulmonary disease (COPD) or a history of cigarette smoking were excluded, and a subgroup analysis was performed in patients who did not receive concurrent treatments such as antibiotics, mucolytics or systemic steroids that may affect lung function improvement. RESULTS: A total of 230 patients (males: 32.6%, median age: 60 years) were analyzed. Their mean forced expiratory volume in 1 second (FEV(1)) was 53.3% of the predicted value [standard deviation (SD), 15.3]. The patients received LAMA (n=95), LABA (n=36), or both (LAMA-LABA; n=99), after which their FEV(1) values were increased by 0.102 liters (SD, 0.208; P<0.001), 0.133 liters (SD, 0.181; P<0.001), and 0.122 liters (SD, 0.230; P<0.001), respectively. In a subgroup of 97 patients who did not receive concurrent treatments, the FEV(1) was increased by with 0.107 liters (SD, 0.167; P<0.001), 0.165 liters (SD, 0.209; P=0.005), and 0.165 liters (SD, 0.187; P<0.001) in the LAMA, LABA, and LAMA-LABA groups, respectively. Baseline FEV(1) had a significant negative correlation with response to bronchodilator treatment in the total patient cohort (R=−0.242, P<0.001) and the subgroup of patients without concurrent treatments (R=−0.386, P<0.001). CONCLUSIONS: Treatment with bronchodilators such as LAMA or LABA was effective in improving lung function in patients with bronchiectasis, regardless of concurrent treatments that also improve lung function. These data may support the use of LAMA and LABA in patients with bronchiectasis.
format Online
Article
Text
id pubmed-7867804
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher AME Publishing Company
record_format MEDLINE/PubMed
spelling pubmed-78678042021-02-09 Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study Lee, Su Yeon Lee, Jae Seung Lee, Sei Won Oh, Yeon-Mok J Thorac Dis Original Article BACKGROUND: Patients with bronchiectasis are often treated with bronchodilators such as long-acting muscarinic antagonists (LAMA) or long-acting beta-agonists (LABA) for their symptoms, but empirical evidence supporting such practice is sparse. We evaluated the effect of LAMA and LABA on lung function improvement in patients with bronchiectasis. METHODS: Using the in-house patient database at a tertiary referral hospital in Seoul, South Korea, we extracted data from patients diagnosed as bronchiectasis with computed tomography (CT) scan and treated with LAMA, LABA, or both. Patients with asthma, chronic obstructive pulmonary disease (COPD) or a history of cigarette smoking were excluded, and a subgroup analysis was performed in patients who did not receive concurrent treatments such as antibiotics, mucolytics or systemic steroids that may affect lung function improvement. RESULTS: A total of 230 patients (males: 32.6%, median age: 60 years) were analyzed. Their mean forced expiratory volume in 1 second (FEV(1)) was 53.3% of the predicted value [standard deviation (SD), 15.3]. The patients received LAMA (n=95), LABA (n=36), or both (LAMA-LABA; n=99), after which their FEV(1) values were increased by 0.102 liters (SD, 0.208; P<0.001), 0.133 liters (SD, 0.181; P<0.001), and 0.122 liters (SD, 0.230; P<0.001), respectively. In a subgroup of 97 patients who did not receive concurrent treatments, the FEV(1) was increased by with 0.107 liters (SD, 0.167; P<0.001), 0.165 liters (SD, 0.209; P=0.005), and 0.165 liters (SD, 0.187; P<0.001) in the LAMA, LABA, and LAMA-LABA groups, respectively. Baseline FEV(1) had a significant negative correlation with response to bronchodilator treatment in the total patient cohort (R=−0.242, P<0.001) and the subgroup of patients without concurrent treatments (R=−0.386, P<0.001). CONCLUSIONS: Treatment with bronchodilators such as LAMA or LABA was effective in improving lung function in patients with bronchiectasis, regardless of concurrent treatments that also improve lung function. These data may support the use of LAMA and LABA in patients with bronchiectasis. AME Publishing Company 2021-01 /pmc/articles/PMC7867804/ /pubmed/33569197 http://dx.doi.org/10.21037/jtd-20-1282 Text en 2021 Journal of Thoracic Disease. All rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0 (https://creativecommons.org/licenses/by-nc-nd/4.0/) .
spellingShingle Original Article
Lee, Su Yeon
Lee, Jae Seung
Lee, Sei Won
Oh, Yeon-Mok
Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study
title Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study
title_full Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study
title_fullStr Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study
title_full_unstemmed Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study
title_short Effects of treatment with long-acting muscarinic antagonists (LAMA) and long-acting beta-agonists (LABA) on lung function improvement in patients with bronchiectasis: an observational study
title_sort effects of treatment with long-acting muscarinic antagonists (lama) and long-acting beta-agonists (laba) on lung function improvement in patients with bronchiectasis: an observational study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7867804/
https://www.ncbi.nlm.nih.gov/pubmed/33569197
http://dx.doi.org/10.21037/jtd-20-1282
work_keys_str_mv AT leesuyeon effectsoftreatmentwithlongactingmuscarinicantagonistslamaandlongactingbetaagonistslabaonlungfunctionimprovementinpatientswithbronchiectasisanobservationalstudy
AT leejaeseung effectsoftreatmentwithlongactingmuscarinicantagonistslamaandlongactingbetaagonistslabaonlungfunctionimprovementinpatientswithbronchiectasisanobservationalstudy
AT leeseiwon effectsoftreatmentwithlongactingmuscarinicantagonistslamaandlongactingbetaagonistslabaonlungfunctionimprovementinpatientswithbronchiectasisanobservationalstudy
AT ohyeonmok effectsoftreatmentwithlongactingmuscarinicantagonistslamaandlongactingbetaagonistslabaonlungfunctionimprovementinpatientswithbronchiectasisanobservationalstudy